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HMGB1 Mediates Anemia of Inflammation in Murine
Sepsis Survivors
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Patients surviving sepsis develop anemia, but the molecular mechanism is unknown. Here we observed that mice surviving
 olymicrobial gram-negative sepsis develop hypochromic, microcytic anemia with reticulocytosis. The bone marrow of sepsis sur
p
vivors accumulates polychromatophilic and orthochromatic erythroblasts. Compensatory extramedullary erythropoiesis in the spleen
is defective during terminal differentiation. Circulating tumor necrosis factor (TNF) and interleukin (IL)-6 are elevated for 5 d after the
onset of sepsis, and serum high-mobility group box 1 (HMGB1) levels are increased from d 7 until at least d 28. Administration of recombinant HMGB1 to healthy mice mediates anemia with extramedullary erythropoiesis and significantly elevated reticulocyte counts.
Moreover, administration of anti-HMGB1 monoclonal antibodies after sepsis significantly ameliorates the development of anemia
(hematocrit 48.5 ± 9.0% versus 37.4 ± 6.1%, p < 0.01; hemoglobin 14.0 ± 1.7 versus 11.7 ± 1.2 g/dL, p < 0.01). Together, these results indicate that HMGB1 mediates anemia by interfering with erythropoiesis, suggesting a potential therapeutic strategy for anemia in sepsis.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2015.00243

INTRODUCTION
Severe sepsis, the clinical syndrome
that occurs in response to infection or
injury (1), occurs in more than 700,000
cases annually in the United States.

†

The mortality rate is >20%; survivors of
severe sepsis have a cumulative 5-year
mortality of 74% (2,3). Anemia, defined
as a decrease in the hematocrit and he
moglobin, is a frequent complication
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of severe sepsis, with >60% of septic
patients developing anemia, and 90%
of these patients will remain anemic for
several weeks (4).
Anemia in the critically ill patient is
a predictor of poor outcome (5). This
“anemia of inflammation” affects patients
with chronic infections, autoimmune dis
orders, and malignancies, as well as
sepsis (6). Hemoglobin levels of 7–9 g/dL
are typical in septic patients (7) and char
acterized by microcytic and hypochromic
erythrocytes (4,8). Despite its high prev
alence and significant adverse impact on
quality of life, the mechanisms of anemia
of inflammation remain u
 nclear (7).
Patients with sepsis develop signif
icant long-term elevations in circulat
ing HMGB1 levels that correlate with
in-hospital mortality (9). HMGB1 is a
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proinflammatory cytokine that exists in
three redox isoforms, termed disulfide,
all-thiol and sulfonyl, each possessing
differential signaling activities (10,11).
Disulfide HMGB1 binds to the cell sur
face receptor complex MD2-TLR4 (12)
to enhance release of TNF and IL-6,
cytokines that have been implicated in
the onset of anemia of inflammation in
sepsis and negatively regulate erythro
poiesis (13,14). We recently identified
HMGB1 as a mediator of persistent mor
bidity and mortality in sepsis survivors
(15,16). Here we show that HMGB1 is
both necessary and sufficient to induce
anemia in murine sepsis survivors and
that HMGB1 is a therapeutic target.
MATERIALS AND METHODS
Mice
All experiments were performed in
accordance with the National Institutes
of Health guidelines, under protocols
approved by the Institutional Animal
Care and Use Committee of the Feinstein
Institute for Medical Research. Male
BALB/c mice were purchased from
Charles River. Mice were 3–4 months old
at the moment of surgery and weighed
between 25 and 28 g. Mice were housed
in groups of five in a pathogen-free
facility in an enriched environment. Ani
mals were on a 12-h daylight cycle with
ad libitum access to water and normal
chow. After cecal ligation and puncture
(CLP), investigators and technicians from
the Feinstein animal facility ascertained
animal welfare twice a day.
Induction of Sepsis
Severe polymicrobial abdominal sepsis
was induced in BALB/c mice by CLP as
previously described (15). Briefly, after
isolation of the cecum, we ligated below
the ileo-cecal valve and punctured it
once with a 22-G needle. Stool (~1 mm)
was mechanically extruded, the cecum
returned to the abdominal cavity and the
wound closed with surgical clips. Resus
citation immediately after CLP included
1 mL saline solution, as well as a dose of
Imipenem-Cilastatin (0.5 mg/kg diluted

in a 0.9% saline solution), both adminis
tered subcutaneously. Survival rates in
the CLP model are typically between
50 and 70%.
Recombinant HMGB1 Administration
to Healthy BALB/c Mice
Recombinant rat HMGB1 was ex
pressed in Escherichia coli and purified as
previously described (17). Recombinant
disulfide HMGB1 was prepared as de
scribed elsewhere (18,19), 500 μg diluted
in 650 μL phosphate-buffered saline
(PBS) and administered intraperitoneally
to healthy BALB/c mice daily for 21 d.
Control mice received PBS injections.
This dose of HMGB1 induces an inflam
matory response that lasts ~24 h. One
day after the last injection, blood, bone
marrow and spleen were harvested.
Administration of Anti-HMGB1
Neutralizing Monoclonal Antibody
The anti-HMGB1 monoclonal antibody
(clone 2G7) was generated as previously
described (20). This is a neutralizing an
tibody that detects all redox isoforms of
HMGB1. It does not need complement
activation or Fc-receptor interactions
to perform as an HMGB1 antagonist. It
does not react with HMGB2. The mono
clonal antibody detects an epitope in
sequence 46–63 of the box A domain, more
specifically around glycine in position
58, since this is the single discriminating
residue between HMGB1 and HMGB2
in this sequence. On d 9–11 after surgery,
CLP survivors received intraperitoneal
injections of either anti-HMGB1 mono
clonal antibody (50 μg/day in 200 μL
PBS) or mouse IgG2b (ESMD Chemicals)
as isotype control (15). Specificity of
2G7 has been previously demonstrated
(15,16).
Complete Blood Counts
Blood was collected by cardiac
puncture and transferred to ethylene
diaminetetraacetic acid (EDTA)-coated
tubes. Complete blood counts were ob
tained using the automated hematology
analyzer AcT diff (Beckman Coulter).
Reticulocytes were determined by flow
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cytometry using Thiazole orange (Retic
Count®; BD Biosciences) according to
the manufacturer’s instructions.
Characterization of Murine
Erythropoiesis
To evaluate stress erythropoiesis,
spleens were flushed with 1 mL ice-cold
PBS, and cells were expelled using gentle
compression. Bone marrow cells were
obtained after dislocating two limbs and
two long bones. Bones were cleaned and
the epiphysis cut. Each diaphysis was
then flushed with PBS repeatedly until no
obvious macroscopic hematopoietic tissue
remained. Flushed cells (splenic and bone
marrow) were homogenized into single
cell solution, filtered using a 40 μmol/L
sterile cell strainer (Fisherbrand®;
Fisher Scientific).
To quantitate the degree of eryth
ropoiesis in the bone marrow and the
spleen of animals, we used positive
magnetic sorting with anti-CD45 beads
(Milteny Biotec). Erythropoiesis was
monitored as described previously (21).
Briefly, we gated on CD45neg, CD11bneg
and GR-1neg cells within the 7-AADneg
gate. Those cells were then gated on
Ter119+ cells, followed by CD44 versus
forward scatter. This revealed six differ
ent cell populations corresponding to the
six stages of terminal erythroid differen
tiation. All flow data were subsequently
analyzed using FlowJo v9.4 (Tree Star).
Cytokine Determination
Erythropoietin (EPO) and ferritin were
determined by enzyme-linked immu
nosorbent assay (ELISA) according to
manufacturer instructions: EPO (R&D Sys
tems, cat: MEP00B) and ferritin (Abcam,
cat. no. ab157713). The levels of TNF and
IL-6 were determined using a mouse a
multiplex kit (Meso Scale Discovery),
according to the manufacturer’s instruc
tions. HMGB1 levels were measured by
immunoblotting analysis as described
previously (19). Briefly, plasma samples
were loaded on sodium dodecylsulfate–
polyacrylamide gel electrophoresis
(SDS-PAGE) and electrically transferred
to a poly(vinylidene difluoride) (PVDF)
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immunoblot membrane (Bio-Rad). After
blocking, membranes were probed with
either specific anti-HMGB1 antiserum
or purified IgG from anti-HMGB1 an
tiserum for Western blot analysis. The
levels of HMGB1 were determined by
reference to standard curves generated
with purified HMGB1, and the relative
band intensity was quantified by ImageJ
(National Institutes of Health).
Spleen Histopathology
Whole spleens were harvested and fixed
using 4% (vol/vol) paraformaldehyde-PBS.
The samples were then sent to AML
Laboratories for processing, slicing and
hematoxylin and eosin (H&E) staining.
Photomicrographs were obtained on a
Zeiss Axio Imager Z.1 with an Axiocam
506 color camera and further processed
using Zen software to match exposure
and color balance across specimens.
Statistics
Data are expressed as mean ± standard
deviation (SD). Differences between
means were determined by using a twotailed t test. p values <0.05 were consid
ered significant.
RESULTS
HMGB1 Is a Mediator of Anemia
in Sepsis Survivors
To study the development of anemia
of inflammation during sepsis, we in
duced severe sepsis in BALB/c mice
by CLP, using an established protocol
with survival rates of 50–70% (15). Com
plete blood counts, obtained for up to
28 d after CLP, revealed a significant
decrease in hematocrit (Figure 1A),
hemoglobin (Figure 1B) and red blood
cells (Figure 1C) as early as 3 d after
the onset of sepsis that persisted for at
least 28 d in survivors, except for the
number of red blood cells. The anemia
was normocytic and normochromic for
at least 7 d, thereafter becoming micro
cytic and hypochromic, as evidenced by
progressive decreases in the mean corpus
cular hemoglobin (MCH) and mean cor
puscular volume (MCV) (Figures 1D, E).

During the first week after CLP, the
reticulocyte count was significantly
decreased in CLP survivors compared
with sham animals (Figure 1F). Circu
lating EPO levels increased from d 5–7
(not shown), followed by a transient in
crease in the reticulocyte count on d 15
(Figure 1F). These results indicate that
a microcytic, hypochromic anemia per
sists for at least 28 d in murine severe
sepsis survivors. The ferritin levels were
elevated during the first 2 wks after
CLP compared with the sham group
(not shown), precluding a possible iron
deficiency in the CLP model.
Prolonged experimental adminis
tration of recombinant TNF induces
anemia and reduces red blood cell sur
vival (14), and IL-6 negatively regulates
erythropoiesis, in part by inducing hep
cidin (13,22). However, TNF and IL-6
increase only transiently after sepsis
onset in patients, returning to normal
levels as anemia persists (23). CLP
survivors had a rapid and transient in
crease in IL-6 and TNF, but circulating
levels of those cytokines returned to
levels similar to the sham group after
d 5 (Figures 1G, H). Hepcidin, a master
regulator of iron bioavailability, is re
duced in response to acute blood loss,
resulting in increased intestinal absorp
tion of iron (7). During inflammation,
IL-6 induces hepcidin, leading to hypo
ferrinemia and anemia (13). Circulating
hepcidin was elevated only transiently
7 d after CLP (data not shown). In con
trast to other inflammatory mediators,
circulating HMGB1 increased after d 7
and remained elevated for at least 28 d
(Figure 1I), a pattern consistent with
previous observations that HMGB1
is a late-occurring mediator of sepsis.
This result indicates a role for HMGB1
in sustaining the anemic phenotype in
CLP survivors.
To study the mechanism of anemia in
mice surviving sepsis, spleen and bone
marrow were collected from animals
10 d after the onset of sepsis. We recently
demonstrated the expansion of the leu
kocyte compartment in the spleen of CLP
survivors (15). In agreement with these

results, we observed that the spleens are
macroscopically enlarged (Figure 2A).
Analysis of spleen sections revealed
disruption of the normal architecture,
with expansion of the red pulp that is
characteristic of stress erythropoiesis
(24) (Figure 2B). After depletion of the
CD45pos compartment (that is, lymphoid
populations), splenocytes were ana
lyzed by flow cytometry on the basis of
the expression of the erythroid marker
Ter119. Ter119+ cells were then analyzed
by CD44 expression and forward scat
ter as previously described (21). CD44,
the hyaluronate receptor, presents an
expression pattern that decreases over
30-fold during terminal erythroid dif
ferentiation (25). The different stages of
terminal erythroid differentiation, from
pro- to orthochromatic erythroblasts,
were significantly expanded in the CLP
survivors (Figures 2C, D). Bone marrow
cell mass was reduced, both before and
after depletion of the lymphoid compart
ment, but was not statistically significant
(Figure 2E). Flow cytometry analyses
revealed significant increases in the eryth
roid precursor population with accumu
lation of orthochromatic erythroblasts
(Figures 2F, G). During erythropoiesis,
there is progressive expansion and dif
ferentiation with one proerythroblast (P)
producing two basophilic (B), four poly
chromatophilic (Po) and eight orthochro
matic (O) erythroblasts (21). In the CLP
animals, we observed that the progres
sion toward orthochromatic erythroblasts
in the bone marrow is altered, with the
ratio becoming 1 (P), 1.8 (B), 5 (Po) and
11.6 (O). This accumulation of late-stage
cells indicates that defective erythropoi
esis contributes to the anemia phenotype
and that there is an increased production
of red cell precursors in both cellular
compartments.
HMGB1 Induces Anemia and Stress
Erythropoiesis in Mice
We then administered rHMGB1 to
BALB/c mice for 21 consecutive days
and observed the onset of anemia
within 7 d, characterized by a signifi
cant increase in the reticulocyte count
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Figure 1. Sepsis survivors develop sustained anemia, as well as a delayed elevation in HMGB1. Mice were subject to CLP to induce
severe sepsis, or sham surgery as control. Compete blood counts were performed at prespecified time points (A–F). TNF (G) and IL-6 (H)
were measured by multiplex ELISA. HMGB1 was determined by semiquantitative immunoblotting (I). Data are expressed as mean ± SD
(n = 4–5 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001 versus sham.

(Figure 3A). Total cell counts in the
bone marrow did not differ significantly
between groups (1.1 ± 0.3 × 108 cells
versus 0.79 ± 0.3 × 108cells, respectively;
p = 0.2). We found, however, a sig
nificant depletion of the erythroid
compartment in animals exposed to
HMGB1 (0.25 ± 0.05 × 108 cells ver
sus 0.1 ± 0.02 × 108 cells, respectively;
p < 0.001) (Figure 3B). We also observed
an expansion of erythropoiesis in the
bone marrow in response to HMGB1,
with an accumulation of polychro
matophilic and orthochromatic eryth
roblasts (Figures 3C, D) and a ratio of
1 (P), 1.5 (B), 3.9 (Po) and 9.1 (O). The
degree of abnormality was clearly less
in the rHMGB1-treated animals than in

CLP [1 (P), 1.8 (B), 5 (Po) and 11.6 (O)].
Macroscopic examination of the spleens
revealed that injecting HMGB1 induced
splenomegaly (Figure 3E). Analysis of the
spleen showed increased total cellularity
(1.9 ± 0.05 × 108 cells in the vehicle group
versus 3.8 ± 1.1 × 108 cells in the HMGB1treated group; p = 0.035) and specific
expansion of the erythroid compartment
(0.86 ± 0.2 × 108 versus 1.7 ± 0.2 × 108,
respectively; p = 0.002) (Figure 3F).
Flow cytometry analyses revealed that
exposure to HMGB1 led to increased
erythropoiesis (Figure 3G), with signifi
cant increases in the four populations of
precursors from pro- to orthrochromatic
erythroblast (Figure 3H) when compared
with the untreated group.
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Administration of Anti-HMGB1
Monoclonal Antibodies Ameliorates
Anemia in the CLP Model
To evaluate the role of HMGB1 in the
anemia of sepsis, mice received neutral
izing monoclonal anti-HMGB1 antibody
(clone 2G7) or isotype control (IgG-2b) on
d 9–11 after CLP. The rationale for treat
ing the mice at this point was to evaluate
the effect of neutralizing HMGB1 after
anemia onset. Sepsis survivors receiv
ing isotype control developed persistent
anemia, whereas survivors receiving the
anti-HMGB1 had similar levels of hemo
globin and hematocrit as the sham group
(Figures 4A, B). Although hemoglobin and
hematocrit normalized within days after
the administration of anti-HMGB1, MCH

RESEARCH ARTICLE

Figure 2. Sepsis survivors have defective terminal erythroid differentiation. Spleen and bone marrow were obtained from sepsis survivors
10 d after mice were subjected to CLP or sham surgery. CLP survivors developed splenomegaly (A) and an expansion of the red pulp
(B), suggesting stress erythropoiesis. Dash borders denote the separation between the red pulp (rp) and the white pulp (wp). Numerical
apertures for the different magnifications: 10× = 0.45; 20× = 0.80; 40× = 0.75; 63× oil = 1.4. Scale bar: 125 μm (10×), 62 μm (20×), 31 μm
(40×) and 20 μm (63×). Analysis of the erythroid compartment by flow cytometry shows an expansion of immature erythroid cells in the
spleen of CLP animals (C, D). Bone marrow total cellular content was not different between groups, either before or after depletion (E).
Flow analysis shows an increase in orthochromatic erythroblasts (F, G). Cell counts of total and post-depletion bone marrow represents
the number of cells from femur and tibia obtained from both hind limbs. Data shown are mean ± SD (n = 3–4 mice/group).

remained lower in CLP survivors than in
the sham group 3 wks after CLP, indepen
dent of treatment (data not shown). MCV
showed a trend to normalizing in the
treated group (data not shown).
DISCUSSION
HMGB1 is a mediator in the immune-
pathogenesis of severe sepsis (18,20,26)
and also induces renal (27) and cognitive

dysfunctions (16). Our present study
reveals a novel role for HMGB1 in the
pathogenesis of anemia of inflammation
in sepsis survivors.
Anemia can result from increased red
cell destruction or defective red cell pro
duction. Although we did not measure
red cell survival in our murine model
of sepsis survivors, we did observe that
erythropoiesis is defective in the bone

marrow of the CLP animals. Indeed,
during normal terminal erythroid dif
ferentiation, three mitoses lead to the
production of eight orthochromatic
erythroblasts from one proerythroblast.
Therefore, a ratio of 1:2:4:8 is normally
observed under steady-state conditions.
In the CLP model, however, we ob
served a ratio of 1:1.8:5:11.6, suggesting
that the defect occurs between basophilic
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Figure 3. HMGB1 induces anemia and impairs late erythropoiesis. BALB/c mice were injected with rHMGB1 (500 μg/mouse/d, intraperitoneally) or vehicle for 7 d; blood, spleen and bone marrow were collected 24 h after the last injection. (A) HMGB1-induced anemia
with an elevated reticulocyte count. (B) Bone marrow total cellular content was not different between groups, but the erythroid compartment was significantly reduced. (C, D) Analysis of the erythroid compartment by flow cytometry shows an expansion of terminal
erythroid precursors. (E) Administration of HMGB1 also induced splenomegaly (scale bar: 1 cm). (F) Analysis of the splenic cell compartment showed that the total cell count, as well as the erythroid compartment (post–CD45 depletion), were significantly increased. (G, H)
Flow cytometry analyses indicated an increase in the different erythroid populations. Data are expressed as box and whisker plots (A) or
mean ± SD (B, D, F, H) (n = 3–4 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle.
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Figure 4. Neutralizing HMGB1 reverses anemia in sepsis survivors. CLP survivors were randomly
assigned to receive 50 μg/mouse/day of either neutralizing anti-HMGB1 mAb (2G7) or isotype control on d 9–11 after CLP. Whole blood was collected on d 21 or 28 after CLP (4 and
10 d after the last dose of 2G7). Administration of 2G7 rescued septic mice from anemia, as
determined by evaluation of the hemoglobin (A) and hematocrit (B) parameters. Data are
mean ± SD (n = 4–5 mice/group). *p < 0.05, **p < 0.01, ***p < 0.001.

and orthochromatic stages, with in
creased numbers of mitotic events. Data
collected 3 wks after CLP revealed that
hematologic recovery is occurring be
cause red blood cell numbers return to
normal levels. This result is consistent
with increased production, although
resulting in smaller red cells containing
less hemoglobin. This step produces a
microcytic and hypochromic phenotype
that persists in sepsis survivors.
Inflammatory cytokines have been
implicated in the anemia of inflam
mation. Prolonged administration of
recombinant TNF induces anemia and
reduces red blood cell survival (14,28).
IL-6 negatively regulates erythropoiesis,
in part by inducing hepcidin (13,22,29).
In the CLP model, IL-6 peaked 24 h
after CLP, with plasma concentrations

 ecreasing rapidly before manifestation of
d
anemia, suggesting a role for IL-6 only
in the early stages preceding the onset
of anemia. Hepcidin is another import
ant mediator in anemia of inflammation
and, during systemic inflammation,
hepcidin production leads to a reduction
in iron availability for erythropoiesis
(30). In the CLP model, we found that
the hepcidin levels were only transiently
increased, going back to normal within
7 d after surgery. Moreover, the admin
istration of rHMGB1 failed to induce a
significant increase in circulating hepci
din, together suggesting that hepcidin
does not play a significant role in the
prolonged phase of anemia after sepsis.
Plasma levels of HMGB1 were not
significantly increased for the first 7 d
after CLP, but they remained persistently

elevated thereafter, suggesting a role
for HMGB1 in the chronic phase. To
evaluate this possibility, we adminis
tered recombinant HMGB1 for 21 d and
observed an increase in the reticulocyte
count as well as splenomegaly and
stress erythropoiesis. We also observed
a reduction in total hemoglobin as well
as MCH, a similar pattern to the one
observed in CLP survivors, where hypo
chromic anemia developed before micro
cytosis. This result suggests that HMGB1
may induce anemia by interfering with
hemoglobin homeostasis. In the bone
marrow compartment of animals re
ceiving HMGB1, we observed increased
populations of all terminal erythroid
stages, and the ratios from pro- to
orthochromatic were closer to normal
[1 (P), 1.5 (B) 3.9 (Po), 9.1 (O)], indicating
that rHMGB1 induces an increase in the
number of mitoses.
Monoclonal anti-HMGB1 antibodies
have been studied in animal models
of sepsis (20), endotoxin (31), ischemia
reperfusion (32), chronic infectious
arthritis (33), pain and transplanta
tion (34). Here, the administration of a
monoclonal anti-HMGB1 antibody (2G7)
conferred significant protection against
anemia, indicating that HMGB1 is neces
sary for pathogenesis of anemia in sepsis
survivors.
CONCLUSION
Our results suggest a novel role for
HMGB1 in the pathogenesis of anemia of
inflammation in severe sepsis survivors
and that HMGB1 may be a therapeutic
target in the treatment of anemia of
inflammation. Together, these results
define a new model of anemia similar
to the clinical scenario (4), which can be
targeted with a monoclonal antibody
toward therapeutic advantage in sepsis
survivors.
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